Liraglutide as add-on to Insulin in Type 1 Diabetes

Inclusion Criteria:

• Age: 18-70 years

• BMI: 18-28

• HbA1c ≥ 8 %

• No residual β-cell function (glucagon test with c-peptide < 60 pM)

• Caucasian

• Diagnosed with type 1 diabetes at 5 to 40 years of age (both inclusive).

• Remission phase must be completed

• Female participants must use adequate contraception

• Informed consent

Exclusion Criteria:

• Overt diabetes complications; creatinin > 130 µM, proliferative retinopathy,macroalbuminuria.

• Autonomic neuropathy (RR-variation </=10 beats/min) and/or Orthostatic hypotension (OH).

• Anemia, Hb concentration; female <7.0 mmol/l, male<8.0 mmol/l

• Pregnancy or lactation

• Epilepsy

• Use of antiepileptic medication

• Use of beta blockers

• Previously apoplexy cerebri.

• Any use of benzodiazepine within the last month

• Any use of neuroleptic drugs within the last six months

• Self-perceived hearing loss

• Alcohol or drug abuse

• Allergy to the medication or placebo.

• Treatment with any medication affecting glucose metabolism.

• Any disorder which in the investigators opinion could interfere with the safety andresults of the trial